MarketBeat reported on stock consensus ratings, while Decoy Therapeutics announced a partnership with Fox Chase Cancer Center.
1 report, 1 independent
Updated Jun 28
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
MarketBeat reported on stock consensus ratings, while Decoy Therapeutics announced a partnership with Fox Chase Cancer Center.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
MarketBeat
American personal finance blog
-
Fox Chase Cancer Center
research facility and hospital, United States
Nothing else this week.
Related events
- TD Cowen upgraded Maze Therapeutics shares to a strong-buy rating, with coverage reported by MarketBeat.
- MarketBeat reported analyst recommendations for Cytokinetics and Gain Therapeutics, two competing healthcare companies.
- MarketBeat reports on company ratings and targets for Nikon Corporation and Jabil, comparing business profiles and financial health.
- MarketBeat provided average stock rating data, Benzinga reported on Alexander's price objective trim, and BNY Mellon and HSBC acquired new stakes.
- MarketBeat reported analyst ratings for Maze Therapeutics, which utilizes the Compass platform, highlighting competition among healthcare companies.